Payment overview · 2025
General Payments
$267.18
14 reported records · 9 companies
Healthcare provider profile · identity verified
Kiritkumar A Parmar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VINELAND, NJ · NPI 1396813614
Verified facts
What the public records show
CMS Open Payments records show Kiritkumar A Parmar, MD received $267.18 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.94 | 19.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.54 | 14.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.29 | 12.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.66 | 12.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.39 | 11.4% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.88 | 9.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.66 | 8.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.33 | 6.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.49 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.18 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.29 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.29 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.39 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 443 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 116 |
| Metformin Hcl | Metformin Hcl | 351 | 100 |
| Simvastatin | Simvastatin | 260 | 68 |
| Lisinopril | Lisinopril | 247 | 60 |
| Alprazolam | Alprazolam | 206 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 49 |
| Omeprazole | Omeprazole | 186 | 40 |
| Tramadol Hcl | Tramadol Hcl | 165 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 40 |
| Losartan Potassium | Losartan Potassium | 149 | 46 |
| Buspirone Hcl | Buspirone Hcl | 147 | 32 |
| Gabapentin | Gabapentin | 143 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 141 | 48 |
| Alendronate Sodium | Alendronate Sodium | 138 | 36 |
| Furosemide | Furosemide | 131 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 35 |
| Famotidine | Famotidine | 124 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 41 |
| Montelukast Sodium | Montelukast Sodium | 120 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 33 |
| Carvedilol | Carvedilol | 94 | 25 |
| Ezetimibe | Ezetimibe | 94 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 24 |
| Eliquis | Apixaban | 89 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 21 |
| Donepezil Hcl | Donepezil Hcl | 86 | 26 |
| Meclizine Hcl | Meclizine Hcl | 82 | 33 |
| Sertraline Hcl | Sertraline Hcl | 82 | 22 |
| Repaglinide | Repaglinide | 81 | 19 |
| Atenolol | Atenolol | 79 | 22 |
| Calcitriol | Calcitriol | 78 | 19 |
| Meloxicam | Meloxicam | 78 | 22 |
| Mirtazapine | Mirtazapine | 77 | 18 |
| Trazodone Hcl | Trazodone Hcl | 75 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 13 |
| Januvia | Sitagliptin Phosphate | 72 | 21 |
| Farxiga | Dapagliflozin Propanediol | 67 | 15 |
| Azithromycin | Azithromycin | 65 | 59 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Celecoxib | Celecoxib | 61 | 15 |
| Prednisone | Prednisone | 61 | 49 |
| Glimepiride | Glimepiride | 59 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 21 |
| Jardiance | Empagliflozin | 58 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 13 |
| Allopurinol | Allopurinol | 55 | 12 |
| Metformin Hcl Er | Metformin Hcl | 55 | 16 |
| Enalapril Maleate | Enalapril Maleate | 50 | 12 |
| Potassium Chloride | Potassium Chloride | 49 | 15 |
| Rybelsus | Semaglutide | 48 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 18 |
| Finasteride | Finasteride | 44 | 11 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Pregabalin | Pregabalin | 35 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 18 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Glipizide | Glipizide | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | 12 |
| Lactulose | Lactulose | 29 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 26 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 16 |
| Ramipril | Ramipril | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 11 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 16 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Invokana | Canagliflozin | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Methimazole | Methimazole | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 11 |
| Budesonide | Budesonide | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.18 · 14 records | Amgen Inc. | EVENITY, GEMTESA, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VYKAT XR, WATCHMAN Access System, ZEPBOUND, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error